HAIFA,
Israel, July 16, 2024 /PRNewswire/ -- Nurami
Medical, a pioneering developer of soft tissue repair solutions,
announced today that it has been awarded blended financing which
includes a €2.5 million grant and additional equity investment from
the European Innovation Council (EIC) Horizon Accelerator program.
This substantial award recognizes Nurami's innovative technology
and its potential to transform the soft tissue repair industry.
Already in the market with its inaugural product,
ArtiFascia®, a novel dura repair graft launched in the
US and awaiting CE approval, Nurami will utilize the EIC funding to
advance the development of its second product, currently in
pre-clinical trials.
Selected from a competitive field of applicants through a
rigorous evaluation process, Nurami and its groundbreaking
technology, leveraging unique combinations of electrospun polymers
and smart materials, stand out. This recognition serves as
robust validation of Nurami's technology and its compelling value
proposition for soft tissue repair
About Nurami Medical Ltd.
Nurami Medical Ltd. is a medical device company co-founded in
2014 by Dr. Amir Bahar and
Nora Nseir Manassa, experts in
nanofibers and biomaterials. The company develops innovative
implants and sealants that are based on electrospun fibers and
advanced materials to improve patient outcomes and enhance recovery
in soft tissue related surgeries. Nora Nseir Manassa and Hannoch Marksheid are
co-CEOs and Dr. Amir Bahar is COO,
Clinical Director and a member of the company's Board of
Directors.
Logo:
https://mma.prnewswire.com/media/2190078/4814193/Nurami_Logo.jpg
Contact details:
Nora Nseir
Nora@nurami-medical.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nurami-medical-awarded-a-2-5-million-eic-grant-to-accelerate-soft-tissue-repair-302198044.html
SOURCE Nurami Medical